He has served as Chief Executive Officer and Board Director of Reaction Biology, since March of 2022, and a member of the Board of Directors of Xeris Biopharma Holdings, Inc. serving on the Nominating and Corporate Governance Committee and Axogen, Inc. serving on the compensation committee and chair of the Quality, Compliance, and Portfolio committee. He served from 2005-2007 as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, responsible for the Biotechnology, Immunology, and Oncology commercial businesses. Previously, Mr. Johnson served from September 2009 to January 2011 as president of Eli Lilly & Company's Worldwide Oncology Unit, following the company's 2008 acquisition of ImClone Systems, Inc., where he served as Chief Executive Officer and a member of ImClone's Board of Directors from August 2007 until October 2008.